Risks and Safety Considerations of Psilocybin

Psilocybin's legal status in Australia: start here

Forty-three papers into a late-night reading session, I had to remind myself to check my own country's law first. That's the discipline this topic demands. So: in Australia, psilocybin is classified as a Schedule 9 prohibited substance under the Poisons Standard (the document that gives legal force to Australia's scheduling framework). Possession, use, or supply outside a specific and narrow legal pathway is a criminal offence under both Commonwealth and state/territory law.

That narrow pathway opened in July 2023, when the Therapeutic Goods Administration (TGA) approved a rescheduling that permits Authorised Prescribers , specialist psychiatrists who have received formal TGA approval , to prescribe psilocybin as a Schedule 8 controlled drug for specific patient cohorts. This is not a general prescription pathway. It does not apply to GPs. It does not mean psilocybin is freely available. Outside that Authorised Prescriber framework, the substance remains Schedule 9: prohibited.

Understanding what the research says about psilocybin's risks is legitimate and worthwhile , researchers, regulators, and curious people all benefit from accurate information. But this article is descriptive and educational only. It does not constitute medical advice, it does not describe a protocol to follow, and it does not encourage anyone to obtain or use psilocybin outside the lawful Authorised Prescriber framework.

What psilocybin actually is, chemically

Psilocybin is a naturally occurring tryptamine alkaloid found in certain species of fungi. After ingestion, it is rapidly dephosphorylated in the body to its active form, psilocin; the compound that produces pharmacological effects. Psilocin's primary mechanism involves agonism at serotonin receptors, particularly the 5-HT2A subtype, which are distributed across the cerebral cortex and are involved in a wide range of perceptual and cognitive processes.

It has no known direct activity at the cannabinoid receptors (CB1 or CB2) that anchor so much of our other content here, and its pharmacokinetics differ substantially from classical cannabis-derived compounds. Half-life of psilocin in blood is roughly three hours in the published literature, though the subjective experience commonly reported in clinical studies outlasts the detectible plasma window. The compound is not considered physically addictive in the way opioids or alcohol are, it produces no significant physical dependence, but that does not mean it is without risk. Not by a long way.

Acute psychological risks: what the research reports

The most consistently documented acute risk is a difficult or distressing psychological experience, often called a "challenging experience" in clinical literature or, colloquially in lay accounts, a "bad trip." Reported features in the research include acute anxiety, panic, paranoia, and; at higher amounts used in studies, temporary loss of a sense of self or perceptual disturbance that some participants found distressing.

A 2016 survey published in the Journal of Psychopharmacology by Carbonaro et al. (2016, doi:10.1177/0269881116649662), which drew on over 1,993 accounts of challenging experiences, found that approximately 7.6% of respondents reported behaviour that put themselves or others at risk of physical harm during the experience. Around 2.6% reported seeking medical attention. These were self-selected retrospective accounts, not controlled trial data, a limitation the authors explicitly flagged; but the scale of the sample gave the figures enough weight to be widely cited in subsequent safety reviews.

Supervised clinical settings use specific screening, preparation, and support protocols precisely because acute psychological distress is a real and documented phenomenon. The Authorised Prescriber pathway in Australia incorporates these requirements. Unsupervised use lacks all of those safeguards. That gap matters.

Who faces elevated risk: contraindications in the literature

Multiple clinical research protocols exclude participants based on risk factors that appear across the literature. These are not arbitrary. People with a personal or family history of psychotic disorders, including schizophrenia and bipolar disorder with psychotic features, are consistently excluded from trials because of evidence suggesting psilocybin can precipitate or exacerbate psychotic episodes in vulnerable individuals.

Other contraindications reported in research protocols include:

• Current or recent use of lithium (documented cases of seizures in combination with serotonergic compounds)
• Serotonin-reuptake inhibitors (SSRIs and SNRIs), which may interact pharmacodynamically and may alter the subjective and physiological response
• Cardiovascular conditions, given that psilocin produces transient increases in heart rate and blood pressure
• Pregnancy or breastfeeding (insufficient safety data)

Honestly, this is where the gap between idealised community accounts and the clinical literature is widest. Lay discussions sometimes frame psilocybin as broadly safe on the basis of its low physical toxicity profile. The acute lethality data does support low physical toxicity at amounts reported in studies. But "low acute toxicity" and "broadly safe for everyone" are not the same statement, and collapsing the two does a disservice to people who are genuinely at elevated risk.

Hallucinogen persisting perception disorder (HPPD)

A less common but documented risk is hallucinogen persisting perception disorder; HPPD. This involves ongoing visual disturbances (geometric patterns, trailing images, halos) that persist after the acute pharmacological effect has ended, sometimes for months or longer. Its prevalence is difficult to quantify because it is likely underreported and because diagnostic criteria require ruling out other causes. It appears to be more common in people with prior heavy psychedelic use and in those who use psychedelics in unsupervised, high-frequency patterns.

The Australian Drug Foundation's resources on psychedelics note visual disturbances among the documented adverse effects. HPPD is not reversible in all cases. That is worth knowing.

The "set and setting" concept: what research says (and what it doesn't)

Clinical researchers frequently emphasise that psychological outcomes appear to be influenced by the person's mindset going into an experience (the "set") and the physical and social environment (the "setting"). This is a genuine research finding, it is not a guarantee or a safety protocol that people can apply at home. The Authorised Prescriber framework in Australia builds structured set-and-setting principles into clinical requirements precisely because the evidence suggests they are not incidental to the risk profile; they are central to it.

I'd argue that the popularisation of "set and setting" in lay discourse has sometimes been used to imply that the right mindset neutralises risk. That reading goes further than the evidence. Participants in controlled trials are screened, prepared, monitored in real time by trained clinicians, and followed up afterwards. Replicating "set and setting" in an unsupervised context is not the same thing.

Legal consequences in Australia: not a footnote

The risk discussion in the scientific literature focuses almost entirely on physiological and psychological harms. In Australia, the legal risk is equally real and often underemphasised. Outside the Authorised Prescriber pathway, psilocybin-containing material is a Schedule 9 prohibited substance. Possession is a criminal offence in every Australian state and territory. Penalties vary by jurisdiction and quantity but include substantial fines and imprisonment.

People reading accounts of overseas clinical or decriminalised contexts sometimes underestimate the Australian legal position. The 2023 rescheduling was significant, it created a lawful clinical pathway where none existed before; but it did not decriminalise personal possession, and it did not create any exemption for community or ceremonial use. The Special Access Scheme provides a separate but also tightly regulated mechanism for unapproved therapeutic goods, and psilocybin under that framework still requires a prescribing doctor and TGA involvement.

I was reading through some of the TGA's post-rescheduling Q&A documentation late one evening, good jazz on in the background, admittedly more distraction than backdrop, and it struck me how clearly the TGA had tried to anticipate exactly this misreading. The language is explicit: clinical pathway yes, general access no.

Research limitations: what we don't yet know

The evidence base for psilocybin is genuinely growing, but most published trials to date involve small sample sizes, highly selected participants (meaning people at elevated risk were systematically excluded), and short follow-up periods. Longer-term population-level data on adverse events in clinical practice is still accumulating; the Authorised Prescriber pathway in Australia is itself a source of emerging real-world data.

We also don't have good data on interactions with many common medications, on the effects of repeated clinical dosing over years, or on subgroups like older adults with multiple comorbidities. The standard phrase "more research is needed" is overused in science writing, but here it reflects a genuine gap rather than a hedge.

The research picture is promising enough for regulators in Australia and several other jurisdictions to have opened specific supervised clinical pathways. It is not complete enough to support a risk-free characterisation of the compound.

Sources

• TGA approves psilocybin and MDMA-assisted psychotherapy, Therapeutic Goods Administration (tga.gov.au)
• Magic Mushrooms drug facts, Australian Drug Foundation (adf.org.au)
• Carbonaro et al. (2016), Survey study of challenging experiences after ingesting psilocybin mushrooms; NCBI/PubMed (ncbi.nlm.nih.gov)
• Johnson et al. (2018), Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function, NCBI/PubMed (ncbi.nlm.nih.gov)

, Daniel Okoro, Psychedelic science & law writer